“…Promising preliminary results suggest targeted gene therapies may lead to significant improvements in management, including pain reduction, a decrease in lesion size, reduced bleeding, and, in some cases, allowing the cessation of regular blood transfusions (Seront et al, 2019; Tole et al, 2021). Eligibility for such trials is typically dependent on confirming a molecular genetic diagnosis for the VA; however, genomic technologies have been difficult to access for patients with VAs in Australian healthcare settings due to the lack of appropriate clinical testing programs, funding/resources, and knowledge (Eljamri et al, 2022).…”